
bluebird bio, Inc. – NASDAQ:BLUE
bluebird bio stock price today
bluebird bio stock price monthly change
bluebird bio stock price quarterly change
bluebird bio stock price yearly change
bluebird bio key metrics
Market Cap | 76.22M |
Enterprise value | 168.61M |
P/E | -0.94 |
EV/Sales | 47.65 |
EV/EBITDA | -0.57 |
Price/Sales | 0.06 |
Price/Book | N/A |
PEG ratio | -0.01 |
EPS | -0.62 |
Revenue | 21.72M |
EBITDA | -228.11M |
Income | -78.36M |
Revenue Q/Q | 17353.52% |
Revenue Y/Y | 322.58% |
Profit margin | -8449.85% |
Oper. margin | -8837.84% |
Gross margin | -184.44% |
EBIT margin | -8837.84% |
EBITDA margin | -1050.01% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freebluebird bio stock price history
bluebird bio stock forecast
bluebird bio financial statements
Dec 2022 | 62K | 32.23M | 51987.1% |
---|---|---|---|
Mar 2023 | 2.38M | 34.04M | 1429.78% |
Jun 2023 | 6.89M | -72.90M | -1058.17% |
Sep 2023 | 12.39M | -71.73M | -578.85% |
Sep 2025 | 84.91M | -16.63M | -19.59% |
---|---|---|---|
Dec 2025 | 99.26M | -9.81M | -9.89% |
Mar 2026 | 93.42M | -23.48M | -25.14% |
Jun 2026 | 108.90M | -18.08M | -16.6% |
Analysts Price target
Financials & Ratios estimates
Dec 2022 | 554902000 | 358.55M | 64.62% |
---|---|---|---|
Mar 2023 | 692736000 | 337.99M | 48.79% |
Jun 2023 | 663393000 | 374.37M | 56.43% |
Sep 2023 | 613608000 | 391.07M | 63.73% |
Dec 2022 | -56.27M | 103.24M | -115K |
---|---|---|---|
Mar 2023 | -86.63M | 82.13M | 130.45M |
Jun 2023 | -72.72M | 6.94M | -445K |
Sep 2023 | -61.84M | 62.08M | -42K |
bluebird bio alternative data
Aug 2023 | 323 |
---|---|
Sep 2023 | 323 |
Oct 2023 | 323 |
Nov 2023 | 323 |
Dec 2023 | 323 |
Jan 2024 | 323 |
Feb 2024 | 323 |
Mar 2024 | 323 |
Apr 2024 | 323 |
May 2024 | 323 |
Jun 2024 | 323 |
Jul 2024 | 323 |
bluebird bio other data
Period | Buy | Sel |
---|---|---|
Jan 2024 | 0 | 3759 |
Feb 2024 | 0 | 9810 |
Mar 2024 | 0 | 17438 |
Jun 2024 | 0 | 3834 |
Sep 2024 | 0 | 35786 |
Dec 2024 | 0 | 3795 |
Patent |
---|
Application Filling date: 28 Jan 2022 Issue date: 18 Aug 2022 |
Application Filling date: 27 Mar 2020 Issue date: 26 May 2022 |
Application Filling date: 20 Mar 2020 Issue date: 19 May 2022 |
Application Filling date: 22 Jan 2020 Issue date: 7 Apr 2022 |
Application Filling date: 13 Dec 2019 Issue date: 27 Jan 2022 |
Application Filling date: 14 Jun 2019 Issue date: 26 Aug 2021 |
Application Filling date: 14 Dec 2018 Issue date: 5 Aug 2021 |
Quarter | Transcript |
---|---|
Q1 2024 11 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 26 Mar 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 7 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 8 Aug 2023 | Q2 2023 Earnings Call Transcript |
Insider | Compensation |
---|---|
Mr. Nick Leschly (1973) Pres & Director | $841,950 |
Mr. William D. Baird III (1972) Principal Financial & Accounting Officer | $718,610 |
Crispr Therapeutics: Now Is The Time To Buy
Hercules Capital: Winning Option In The Financial Services Space
4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024
Agios Pharmaceuticals: Strong Thalassemia Data Makes A Tempting Bull Case
CRISPR Therapeutics: Therapies Of The Future Are Almost Here, But Not Yet
Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is Nonplussed
Buy bluebird bio's Lovo-Cel As It Transforms Sickle Cell Disease Treatment
Beam Therapeutics: Sale Of Rights To Verve's In Vivo Candidates An Odd Decision
Editas Medicine: A Mispriced Contender In The Gene Editing Arena
-
What's the price of bluebird bio stock today?
One share of bluebird bio stock can currently be purchased for approximately $4.99.
-
When is bluebird bio's next earnings date?
Unfortunately, bluebird bio's (BLUE) next earnings date is currently unknown.
-
Does bluebird bio pay dividends?
No, bluebird bio does not pay dividends.
-
How much money does bluebird bio make?
bluebird bio has a market capitalization of 76.22M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 720.04% to 29.5M US dollars.
-
What is bluebird bio's stock symbol?
bluebird bio, Inc. is traded on the NASDAQ under the ticker symbol "BLUE".
-
What is bluebird bio's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of bluebird bio?
Shares of bluebird bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are bluebird bio's key executives?
bluebird bio's management team includes the following people:
- Mr. Nick Leschly Pres & Director(age: 52, pay: $841,950)
- Mr. William D. Baird III Principal Financial & Accounting Officer(age: 53, pay: $718,610)
-
How many employees does bluebird bio have?
As Jul 2024, bluebird bio employs 323 workers.
-
When bluebird bio went public?
bluebird bio, Inc. is publicly traded company for more then 12 years since IPO on 19 Jun 2013.
-
What is bluebird bio's official website?
The official website for bluebird bio is bluebirdbio.com.
-
Where are bluebird bio's headquarters?
bluebird bio is headquartered at 60 Binney Street, Cambridge, MA.
-
How can i contact bluebird bio?
bluebird bio's mailing address is 60 Binney Street, Cambridge, MA and company can be reached via phone at +33 94999300.
bluebird bio company profile:

bluebird bio, Inc.
bluebirdbio.comNASDAQ
375
Biotechnology
Healthcare
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
Cambridge, MA 02142
CIK: 0001293971
ISIN: US09609G1004
CUSIP: 09609G100